Dasatinib in Combination With Revlimid (and Dexamethasone)

NCT00560391 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg
DRUG: Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg
DRUG: Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg
DRUG: Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg
DRUG: Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg

Sponsor

Bristol-Myers Squibb